All In Biotech

Drug Trial Radar · NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

890

Planned (sponsor's estimate)

Start

Feb 26, 2024

Primary completion

Nov 19, 2030

Study completion Aug 19, 2031

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal squamous cell carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast, and cervical second-line/third-line (cervical 2L/3L) cancer.

Conditions

  • Advanced Solid Tumor
  • Melanoma
  • Head and Neck Cancer
  • Gastric Cancer
  • Ovarian Carcinoma
  • Cervical Cancer
  • Endometrial Cancer
  • Bladder Cancer
  • Pancreatic Carcinoma
  • Prostate Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Lung Cancer
  • Breast Cancer
  • Esophageal Squamous Cell Carcinoma

Interventions

  • HER3-DXdDrug

    Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 27 months
  2. Proportion of Participants Achieving a ≥50% Decrease in Prostate-specific Antigen (PSA) (Prostate Cancer Cohort Only)Time frame: Baseline, each cycle before infusion (each cycle is 21 days), and end of treatment, up to approximately 27 months

Locations

97 sites in 16 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • AdventHealth Medical Group Oncology Research at Celebration

    Kissimmee, Florida · Recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Maryland Oncology Hematology, PA

    Rockville, Maryland · Recruiting

  • Health Partners Frauenshuh Cancer Center

    Saint Louis Park, Minnesota · Recruiting

  • Health Partners Cancer Center at Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • Washington University, School of Medicine

    St Louis, Missouri · Recruiting

  • Roswell Park Cancer Institute IDS

    Buffalo, New York · Recruiting

  • Memorial Sloan Kettering Hospital

    New York, New York · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Completed

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Recruiting

  • Icon Cancer Centre Chermside

    Chermside, Australia · Recruiting

  • Monash Medical Centre Clayton

    Clayton, Australia · Recruiting

  • Icon Cancer Centre Hobart

    Hobart, Australia · Recruiting

  • Icon Cancer Centre Townsville

    Hyde Park, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • UZA

    Edegem, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Universitair Ziekenhuis Brussel

    Jette, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Sunnybrook Research Institute

    Toronto, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Canada · Completed

  • BC Cancer - Vancouver

    Vancouver, Canada · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Chu Bordeaux

    Bordeaux, France · Recruiting

  • Centre Georges Franăois Leclerc

    Dijon, France · Recruiting

  • Hopital Claude Huriez - Chu Lille

    Lille, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hăpital de La Timone

    Marseille, France · Recruiting

  • Chu Nantes - Hătel Dieu

    Nantes, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • ICL - Alexis Vautrin

    Vandœuvre-lès-Nancy, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Krankenhaus Nordwest GmbH

    Frankfurt, Germany · Recruiting

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.